curative labs

Curative Labs Inc
3017 SE Milwaukie Ave
Portland, OR 97202
support@curative.com

Final Results Report

Patient Name:	HRYCIUK, JOHN	**Facility:**	OR OHA
Patient MRN:	CUR159750807		
Requisition:	58957552		
Date of Birth:	06/18/1948 (74 years old)	**Kit ID:**	B-546656344451
Sex:	MALE	**Collected:**	07/06/2022 04:12:12 PM PDT
Address:	9610 SW 3RD AVE PORTLAND, OR 97219	**Received:**	07/06/2022 04:30:09 PM PDT
Phone Number:	15033810373	**Released:**	07/06/2022 04:30:09 PM PDT
Email:	john_hyuciuk@yahoo.com	**Specimen Type:**	Abbott Rapid Antigen shallow nasal swab
Physician:	Zalzala, Sajad (1639311509)		

Test	Result
Abbott BinaxNow (Rapid COVID-19 Antigen Test)	**Positive**

Interpretation:

- Positive: SARS-CoV-2 (COVID-19 antigen) was detected
- Negative: SARS-CoV-2 (COVID-19 antigen) was **not** detected
- Indeterminate: the assay is invalid; test should be repeated.

The BinaxNOW™ COVID-19 Ag Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

The BinaxNOW™ COVID-19 Ag Card does not differentiate between SARS-CoV and SARS-CoV2.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.

Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed. Negative results do not rule out SARSCoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

BinaxNOW™ COVID-19 Ag Card is only for use under the Food and Drug Administration's Emergency Use Authorization.

Patient Fact Sheet: https://www.fda.gov/media/141569/download

Health Care Provider Fact Sheet: https://www.fda.gov/media/141568/download

Lab director: Arthur Baca MD, PhD; CLIA # 45D2192800; Sample reviewed at: 07/06/2022 04:00:09 PM PDT; Report generated at: 07/06/2022 06:11:36 PM PDT